BINIMETINIB |
MEKTOVI |
ARRY-438162 |
ARRY 438162 |
NVP-MEK162 |
MEK-162 |
ARRY-162 |
MEK162 |
ARRY 162 |
chembl:CHEMBL3187723 |
pubchem.compound:10288191 |
drugbank:11967 |
chemidplus:606143-89-9 |
Notes | allosteric inhibitor |
Drug Class | Kinase Inhibitors |
FDA Approval | not approved |
Drug Class | Small molecule |
Drug Indications | antiinflammatory agent,DMARD,antineoplastic agent |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
Drug Categories | antineoplastic agents |
Drug Categories | antineoplastic and immunomodulating agents |
Drug Categories | cytochrome p-450 cyp1a2 substrates |
Drug Categories | cytochrome p-450 cyp2c19 substrates |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | map kinase kinase 1, antagonists & inhibitors |
Drug Categories | map kinase kinase 2, antagonists & inhibitors |
Drug Categories | p-glycoprotein substrates with narrow therapeutic index |
Drug Categories | protein kinase inhibitors |
Drug Categories | ugt1a1 substrates |
Drug Categories | ugt1a1 substrates with narrow therapeutic index |
inhibitor (inhibitory) |
allosteric modulator |
inhibitor (inhibitory) |
Novel drug target | Novel Target |
Trial Name | ARRY-162 |
Specific Action of the Ligand | Negative |
inhibitor (inhibitory) |
allosteric modulator |
inhibitor (inhibitory) |
Mechanism of Interaction | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor |
Direct Interaction | yes |
Specific Action of the Ligand | Negative |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
n/a |
inhibitor (inhibitory) |
n/a |
combination therapy | Encorafenib + Binimetinib |
combination therapy | Encorafenib + Binimetinib + Cetuximab |
Evidence Type | Actionable |
n/a |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | decreased response |
Approval Status | Preclinical - Cell culture |
BINIMETINIB | DrugBank Drug Name |
606143-89-9 | CAS Number |
Mektovi | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
MEK162 | Development Name |
Drug Class | Kinase Inhibitors |
Notes | allosteric inhibitor |
Drug Indications | antiinflammatory agent,DMARD,antineoplastic agent |
Drug Class | Small molecule |
FDA Approval | not approved |
D0C4LF | TTD Drug ID |
MEK162 | Primary Drug Name |
MEK162 | Drug Synonym |
BINIMETINIB | GuideToPharmacology Ligand Name |